rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Preethi Sundaram

Chief Strategy Officer

Company insider

Files Form 4 as: Chief Strategy Officer, Catalyst Pharmaceutical.

Every Form 4 they filed

In numbers

Trades disclosed
66
Buys
0
Sells
4
Bought
$0
Sold
$1.3M
Companies
1
Companies where not an officer
0
First trade
28 Dec 2021
Last trade
15 Jul 2026
Last filed
17 Jul 2026

Companies traded

Where they are an officer
Catalyst PharmaceuticalOfficer · Biotechnology · last 15 Jul 20260 buys · 4 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 17 Jul 2026Catalyst PharmaceuticalBiotechnologySEC FORM 4 Code D$1.7M54,804 at $31.50filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—32,257 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—225,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—67,500 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—225,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—67,500 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—68,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—143,193 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—137,553 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—106,873 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—6,855 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—11,206 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—32,257 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—68,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—143,193 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—137,553 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—106,873 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—6,855 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—11,206 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst PharmaceuticalsSEC FORM 4 Code D$1.7M54,804 at $31.50filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Patrick J. McEnanyDirector and Other role · Director and Other at Catalyst Pharmaceuticals, filing Form 4 there in the last year
Donald A. DenkhausDirector · Director at Catalyst Pharmaceuticals, filing Form 4 there in the last year
David S. TierneyDirector · Director at Catalyst Pharmaceuticals, filing Form 4 there in the last year
Steve MillerChief Op. & Scientific Officer · Chief Op. & Scientific Officer at Catalyst Pharmaceuticals, filing Form 4 there in the last year
Richard J. DalyPresident and CEO · President and CEO at Catalyst Pharmaceuticals, filing Form 4 there in the last year